Company Overview
ARRIVENT BIOPHARMA, INC.
AVBPRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
—M
2025 FY
Net Income
-166M
2025 FY
Shares Outstanding
38M
2025 FY
EPS
-4.32USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1868279
Exchange
Nasdaq
Location
US